Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
223 hedge funds and large institutions have $3.31B invested in Array Biopharma Inc in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 88 increasing their positions, 76 reducing their positions, and 37 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 76
3% more capital invested
Capital invested by funds: $3.22B → $3.31B (+$89.7M)
5% less call options, than puts
Call options by funds: $23.1M | Put options by funds: $24.3M
5% less funds holding
Funds holding: 235 → 223 (-12)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
27% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$31.9M |
| 2 |
Alkeon Capital Management
New York
|
+$31M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.5M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$49.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$31.4M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$19.8M |
| 4 |
PC
PointState Capital
New York
|
-$15.9M |
| 5 |
Goldman Sachs
New York
|
-$14.4M |
ARRY Hedge Fund Activity: Q2 2018 in Review
223 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2018, worth a combined $3.31B — up 2.8% from $3.22B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ARRY and 27 opened new positions — a net loss of 10 holders — while 76 trimmed existing stakes and 88 added.
The largest buyer was Morgan Stanley, adding an estimated $31.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $49.8M sold.
- 223 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2018, down from 235 in Q1 2018.
- Funds reported $3.31B of Array Biopharma Inc stock for Q2 2018, up 2.8% quarter-over-quarter.
- 27 funds opened new Array Biopharma Inc positions in Q2 2018 and 37 closed out, a net change of -10 holders.
- The largest Array Biopharma Inc buyer in Q2 2018 was Morgan Stanley, an estimated $31.9M added.
- The largest Array Biopharma Inc seller in Q2 2018 was EcoR1 Capital, an estimated $49.8M sold.
Based on aggregated 13F filings for Q2 2018.